This case study scenario explores how the Inflation Reduction Act (IRA) could significantly impact the development of new non-small cell lung cancer (NSCLC) treatments. Current treatments offer a disease-free survival (DFS) of 66 months and a 5-year overall survival rate of 88%. However, with the IRA, these figures could drop to 28 months for DFS and 78% for the 5-year survival rate. This reduction would affect over 11,000 patients annually, significantly shortening their lifespan and limiting treatment options for this common and deadly cancer.
The analysis was commissioned by the Partnership to Fight Chronic Disease (PFCD) and conducted by Lumanity.
